Experienced in ABO Incompatibility

Friedrich Thaiss

Hamburg, HH, DE 
Experienced in ABO Incompatibility
Hamburg, HH, DE 
OverviewLocationsClinical Research

Overview

Friedrich Thaiss practices in Hamburg, Germany. Mr. Thaiss is rated as an Experienced expert by MediFind in the treatment of ABO Incompatibility. His top areas of expertise are Glomerulonephritis, Cytomegalovirus Infection, Membranous Nephropathy, Kidney Transplant, and Splenectomy.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of ABO Incompatibility.

Gender
Male

Locations

Hamburg, HH, Germany
Other Locations
Eppendorf, HH 20246, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The Role of Pre-formed Alloreactive T Cells on Acute Rejection Episodes and Long-term Graft Outcome in Patients After Living Donor Renal Transplantation
The Role of Pre-formed Alloreactive T Cells on Acute Rejection Episodes and Long-term Graft Outcome in Patients After Living Donor Renal Transplantation
Enrollment Status: Completed
Publish Date: April 19, 2024
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
Enrollment Status: Terminated
Publish Date: July 13, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
View 1 Less Clinical Trial

41 Total Publications

Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy.
Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy.
Journal: Frontiers in transplantation
Published: August 16, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Thaiss's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile